Inovio Pharmaceuticals, Inc. (INO) stock
INONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.69+0.06 (+3.68%)
Close on Nov 18, 2026Market cap $174.74MP/E –Yield –
Inovio Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Inovio Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$79.26M. For fiscal 2025 it was -$86.82M. The highest annual figure on record is -$13.96M in fiscal 2009.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$86.82M | – |
| FY2024 | Dec 31, 2024 | -$112.40M | – |
| FY2023 | Dec 31, 2023 | -$143.94M | – |
| FY2022 | Dec 31, 2022 | -$267.57M | – |
| FY2021 | Dec 31, 2021 | -$301.22M | – |
| FY2020 | Dec 31, 2020 | -$124.08M | – |
| FY2019 | Dec 31, 2019 | -$111.11M | – |
| FY2018 | Dec 31, 2018 | -$94.09M | – |
| FY2017 | Dec 31, 2017 | -$83.64M | – |
| FY2016 | Dec 31, 2016 | -$76.24M | – |
| FY2015 | Dec 31, 2015 | -$34.28M | – |
| FY2014 | Dec 31, 2014 | -$39.50M | – |
| FY2013 | Dec 31, 2013 | -$19.54M | – |
| FY2012 | Dec 31, 2012 | -$23.49M | – |
| FY2011 | Dec 31, 2011 | -$21.64M | – |
| FY2010 | Dec 31, 2010 | -$19.22M | – |
| FY2009 | Dec 31, 2009 | -$13.96M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.62M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.95M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.48M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.21M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.08M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.37M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.35M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.55M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.04M | – |
| Q1 FY2023 | Mar 31, 2023 | -$43.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$55.95M | – |
| Q3 FY2022 | Sep 30, 2022 | -$35.76M | – |
| Q2 FY2022 | Jun 30, 2022 | -$104.14M | – |
| Q1 FY2022 | Mar 31, 2022 | -$71.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$105.51M | – |
| Q3 FY2021 | Sep 30, 2021 | -$59.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$83.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$52.55M | – |
| Q4 FY2020 | Dec 31, 2020 | -$29.34M | – |
| Q3 FY2020 | Sep 30, 2020 | -$36.33M | – |
| Q2 FY2020 | Jun 30, 2020 | -$33.18M | – |
| Q1 FY2020 | Mar 31, 2020 | -$25.23M | – |
| Q4 FY2019 | Dec 31, 2019 | -$30.42M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.95M | – |
| Q2 FY2019 | Jun 30, 2019 | -$28.20M | – |
| Q1 FY2019 | Mar 31, 2019 | -$28.54M | – |
| Q4 FY2018 | Dec 31, 2018 | -$29.50M | – |
| Q3 FY2018 | Sep 30, 2018 | -$26.64M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.20M | – |
| Q1 FY2018 | Mar 31, 2018 | -$32.75M | – |
| Q4 FY2017 | Dec 31, 2017 | -$22.89M | – |
| Q3 FY2017 | Sep 30, 2017 | -$29.19M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.64M | – |
| Q1 FY2017 | Mar 31, 2017 | -$21.93M | – |
| Q4 FY2016 | Dec 31, 2016 | -$22.36M | – |
| Q3 FY2016 | Sep 30, 2016 | -$20.20M | – |
See a number that looks wrong?